Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

236 FLUTAMIDE
(1999): Fisher BJ, Toronto, Ontario (generalized) (from Internet)
(observation)
(1989): Brogden RN+, Drugs 38, 185
Lupus erythematosus
(1998): Reid MB+, JUrol159, 2098
Photosensitivity
(2003): Kaur C+, Br J Dermatol 148(3), 603
(1999): Tsien C+, JUrol162, 494
(1998): Vilaplana J+, Contact Dermatitis 38, 68
(1998): Yokote R+, Eur J Dermatol 8, 427
(1996): Fujimoto M+, Br J Dermatol 135, 496
(1996): Leroy D+, Photodermatol Photoimmunol Photomed
12(5), 216
(1991): Moraillon I+, Photodermatol Photoimmunol Photomed
8, 264
Rash (sic) (3%)
Toxic epidermal necrolysis
Urticaria
Other
Gynecomastia (9%)
(1997): Staiman VR+, Urology 50, 929
(1993): Aso Y+, Hinyokika Kiyo (Japanese) 39, 391
Hepatotoxicity
(2005): Papaioannides D+, Int Urol Nephrol 37(3), 515
Hot flashes (61%)
Injection-site irritation (3%)
Pseudoporphyria
(1999): Mantoux F+, Ann Dermatol Venereol (French) 126, 150
(1999): Schmutz JL+, Ann Dermatol Venereol (French) 126, 374
(1998): Borroni G+, Br J Dermatol 138, 711
FLUTICASONE
Trade names: Cutivate (GSK); Flonase (GSK); Flovent (GSK)
Indications: Dermatoses, rhinitis
Category: Corticosteroid, inhaled; Corticosteroid, topical
Half-life: N/A
Clinically important, potentially hazardous interactions
with: ketoconazole, live vaccines, oral contraceptives, ritonavir
Reactions
Skin
Acne
Atrophy
(1996): Johnson M, Cutis 57(2), 10
Bruising
(2005): Man SF+, Drugs 65(5), 579
Burning
(1996): Johnson M, Cutis 57(2), 10
(1996): Lebwohl M, Cutis 57(2), 62
Edema
Pruritus
(1996): Johnson M, Cutis 57(2), 10
(1996): Lebwohl M, Cutis 57(2), 62
Rash (sic)
Vasculitis
(2003): English J 3rd+, J Drugs Dermatol 2(3), 326
(2002): Koya T+, Arerugi 51(11), 1127
(2001): Termeer C+, Arch Dermatol 137(11), 1527
Mucosal
Oral candidiasis
(2005): Adams NP+, Cochrane Database Syst Rev (4), CD003135
(2005): Lipworth BJ+, Ann Allergy Asthma 94(4), 465 (22%)
(2005): Man SF+, Drugs 65(5), 579
(2004): Donohue JF+, Treat Respir Med 3(3), 173
(2003): Fukushima C+, Ann Allergy Asthma Immunol 90(6), 646
(2003): Hanania NA+, Chest 124(3), 834
(2003): Powell H+, Med J Aust 178(5), 223
(2003): Randell TL+, Paediatr Drugs 5(7), 481 (rare)
(2002): Lyseng-Williamson KA+, Am J Respir Med 1(4), 273
(1999): Spencer CM+, Drugs 57(6), 933
Eyes
Cataract
(2004): Bisgaard H+, Pediatrics 113(2), e87
Ocular pressure
(2004): Sihota R+, Indian J Ophthalmol 52(2), 170
Other
Adverse effects (sic)
(2003): Coghlan D+, Paediatr Drugs 5(10), 685 (rare)
(2000): Kokot M, Pol Merkuriusz Lek 8(47), 330 (%)
(1999): Todd GR, EurRespirJ13(3), 707
(1996): Lebwohl M, Cutis 57(2), 62
Chills
Cough
(2004): Bisgaard H+, Pediatrics 113(2), e87
(2003): Dubus JC+, Fundam Clin Pharmacol 17(5), 627
Death
(2006): Li AM, JPediatr148(3), 294 (with ritonavir)
Fever
Infections
(2002): Bratton RL+, Mayo Clin Proc 77(12), 1353
(2002): Peter E+, Clin Infect Dis 35(5), e54
(2000): Leav BA+, NEnglJMed343(8), 586
(1999): Fairfax AJ+, Thorax 54(9), 860
Myalgia/Myositis/Myopathy/Myotoxicity
(2004): De Swert+, NEnglJMed350(11), 1157
FLUVASTATIN
Trade names: Cranoc; Lescol (Novartis); Locol
Indications: Hypercholesterolemia
Category: HMG-CoA reductase inhibitor; Statin
Half-life: 1.2 hours
Clinically important, potentially hazardous interactions
with: azithromycin, bosentan, ciprofibrate, clarithromycin,
cyclosporine, erythromycin, gemfibrozil, imatinib, red rice yeast
Reactions
Skin
Allergic reactions (sic) (2.6%)
Angioedema
Dermatomyositis
(2005): Thual N+, Ann Dermatol Venereol 132(12), 996
Erythema multiforme
Lichenoid eruption
(2004): Sebok B+, Acta Derm Venereol 84(3), 229
Lupus erythematosus
(1998): Sridhar MK+, Lancet 352, 114 (fatal)
Photosensitivity
Pigmentation
Pruritus
Purpura
Rash (sic) (2.7%)
(1998): N Z Medicines Adverse Reactions Committee (2
patients) (from Internet) (observation)
Stevens–Johnson syndrome